Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan.
Clin Lung Cancer. 2009 Jul;10(4):290-4. doi: 10.3816/CLC.2009.n.040.
S-1 (also known as TS-1; Taiho Pharmaceutical Co. Ltd.; Tokyo, Japan) is a new oral fluoropyrimidine formulation that combines tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate in a molar ratio of 1:0.4:1. Single-agent S-1 has demonstrated marked activity against non-small-cell lung cancer (NSCLC) as well as a broad array of other solid tumors, including gastric, colorectal, breast, cervical, and pancreatic cancers. This comprehensive review summarizes the results of previous clinical studies and describes ongoing clinical trials of S-1 in advanced NSCLC. S-1 combined with platinum compounds, irinotecan, and gemcitabine has produced promising results in terms of feasibility, safety, and effectiveness. Available data have stimulated further research, including phase III trials for the first-line treatment of advanced NSCLC.
S-1（也称为 TS-1；大日本住友制药株式会社；日本东京）是一种新的口服氟嘧啶制剂，它将替加氟、5-氯-2,4-二羟基吡啶（CDHP）和氧嗪酸钾以 1:0.4:1 的摩尔比结合在一起。单药 S-1 对非小细胞肺癌（NSCLC）以及广泛的其他实体瘤（包括胃癌、结直肠癌、乳腺癌、宫颈癌和胰腺癌）显示出明显的活性。这篇全面的综述总结了之前临床研究的结果，并描述了 S-1 治疗晚期 NSCLC 的正在进行的临床试验。S-1 联合铂类化合物、伊立替康和吉西他滨在可行性、安全性和有效性方面取得了令人鼓舞的结果。现有数据激发了进一步的研究，包括 S-1 作为晚期 NSCLC 一线治疗的 III 期临床试验。
